Adds CLN2, MPS IVA, MPS VI, MPS VII, and Fabry diseases to New York's newborn screening panel.

New York S10260 amends the public health law to include CLN2, MPS IVA, MPS VI, MPS VII, and Fabry diseases in the state's newborn screening panel. The bill mandates that tests for these conditions be made available within twelve months of the act's effective date. This expansion aims to enhance early detection and intervention for these rare genetic disorders.

Adds CLN2, MPS IVA, MPS VI, MPS VII, and Fabry diseases to New York's newborn screening panel.

New York S10260 amends the public health law to include CLN2, MPS IVA, MPS VI, MPS VII, and Fabry diseases in the state's newborn screening panel. The bill mandates that tests for these conditions be made available within twelve months of the act's effective date. This expansion aims to enhance early detection and intervention for these rare genetic disorders.